WuXi Biologics Introduces TrueSite TI Cell Line Platform

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched TrueSite TI, a targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies.

Targeted integration is a cellular engineering technique that delivers target expression units to predefined, validated locations in host cells. Unlike random integration or transposase methods, it reduces clone screening to dozens of candidates, supports expression stability, and shortens IND timelines.

TrueSite TI is the fourth generation of WuXi Biologics’ WuXia cell line platform, used in over 1000 molecules over the past decade. It achieves an average monoclonal antibody (mAb) titer above 8.0 g/L, suitable for commercial manufacturing. Over 99% of its clonal cell lines maintain protein stability after 60 generations, reducing titer drop risks during scale-up to over 20,000 L.

The platform supports monoclonal antibodies and complex biologics, such as bispecific antibodies, Fc-fusion proteins, and Fab fragments, with consistent cell line stability and growth profiles. Plus, it enables a six-month IND timeline for clinical trials.

Dr. Chris Chen, CEO of WuXi Biologics, commented: “WuXi Biologics continues to advance its WuXia platform, pushing the boundaries of cell line development. As the fourth generation of the platform, TrueSite TI has achieved dual breakthroughs in both ‘quality’ and ‘efficiency’ of cell lines, enabling our clients to lead the forefront of innovative therapeutics R&D.”